AcquisitionsJul 6, 2026, 08:56 AM
Splash Beverage Acquires Global Rights to CannEpil Epilepsy Therapy
AI Summary
Splash Beverage Group, Inc. announced an exclusive global licensing agreement with Argent BioPharma Limited for CannEpil®, a proprietary cannabinoid-based therapeutic for drug-resistant epilepsy. This acquisition marks a significant step in Splash's strategy to build a differentiated cannabinoid therapeutics platform, leveraging CannEpil's existing international commercialization and pursuing U.S. regulatory advancement. The deal includes a $1 million strategic investment commitment from C/M Capital Partners and involves the forgiveness of $5 million in debt and issuance of $5.5 million in preferred equity.
Key Highlights
- Splash Beverage Group acquired exclusive global licensing rights to CannEpil® from Argent BioPharma.
- CannEpil® is a cannabinoid-based therapeutic for drug-resistant epilepsy (DRE).
- The acquisition supports Splash's strategic shift to a cannabinoid biopharmaceutical platform.
- C/M Capital Partners committed a $1 million strategic investment to support CannEpil's advancement.
- Mercer Street Global Opportunity Fund forgave $5 million of Argent BioPharma's debt.
- Splash issued $5.5 million in preferred equity to Argent BioPharma as part of the consideration.
- Argent BioPharma will receive a 15% royalty on net revenue from worldwide CannEpil sales.
- The agreement grants exclusive worldwide commercialization rights for an initial 20-year term.
Price Impact
More from SBEV